CSIMarket
 
Fulcrum Therapeutics Inc   (FULC)
Other Ticker:  
 
 
Price: $9.7300 $0.13 1.354%
Day's High: $9.97 Week Perf: 2.53 %
Day's Low: $ 9.56 30 Day Perf: 39 %
Volume (M): 496 52 Wk High: $ 9.97
Volume (M$): $ 4,828 52 Wk Avg: $4.57
Open: $9.60 52 Wk Low: $2.25



 Market Capitalization (Millions $) 599
 Shares Outstanding (Millions) 62
 Employees -
 Revenues (TTM) (Millions $) 3
 Net Income (TTM) (Millions $) -99
 Cash Flow (TTM) (Millions $) -61
 Capital Exp. (TTM) (Millions $) 1

Fulcrum Therapeutics Inc
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company that focuses on developing small molecule therapies to treat genetically defined diseases. The company specializes in identifying and targeting key regulatory control points within cells to restore essential gene control mechanisms. Fulcrum Therapeutics aims to address the root causes of diseases such as neurodevelopmental disorders, rare diseases, and genetic muscular disorders. The company utilizes its proprietary product engine to identify potential drug candidates and advance them through preclinical and clinical development.


   Company Address: 26 Landsdowne Street Cambridge 2139 MA
   Company Phone Number: 651-8851   Stock Exchange / Ticker: NASDAQ FULC
   FULC is expected to report next financial results on March 08, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Shares

Fulcrum Therapeutics Empowers New Employees with Inducement Stock Options to Drive Innovation in Rare Genetic Disease Therapies.

Published Thu, Dec 7 2023 9:30 PM UTC


CAMBRIDGE, Mass., Dec. 07, 2023 - Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company dedicated to improving the lives of patients with genetically defined rare diseases, has announced the granting of non-statutory stock options to new employees. This move aims to enhance Fulcrum's workforce by attracting talented professionals to contr...

Fulcrum Therapeutics Inc

Fulcrum Therapeutics Inc Struggles with Revenue Decline and Net Loss, Despite Slight Progress in Q3 2023 Finances

Financial News Report:
Major Pharmaceutical Preparations Company Discloses Disappointing Fiscal Period
In a recent financial report, Major Pharmaceutical Preparations company revealed disappointing results for its most recent fiscal period. The company's revenue experienced a significant decline of -35.841% to $0.76 million. This decline in revenue is in contrast to the overall trend in the Major Pharmaceutical Preparations industry, which posted a revenue gain during the same period.
Furthermore, Fulcrum Therapeutics Inc, a key player in the industry, reported a net loss per share of $-0.39, compared to $-0.51 in the preceding year. This improvement in net loss per share indicates some progress for the company. However, it is important to note that the company still faces challenges, especially considering the fall in revenue experienced during the fiscal period.

Fulcrum Therapeutics Inc

Fulcrum Therapeutics Inc. Sees Definitive Improvement Amid Challenging Q2 2023, Despite Major Revenue Dip

The stock market can be a volatile and unpredictable place, but there are times when positive signs emerge that give investors hope. One such occasion occurred during the April to June 30, 2023 financial period for Fulcrum Therapeutics Inc (FULC), a pharmaceutical company that specializes in major pharmaceutical preparations.
During this period, FULC made significant strides in improving its financial position. The company reduced its loss per share from $-0.83 to $-0.38, showcasing a remarkable improvement in its earnings. Additionally, the company's earnings per share (EPS) went from $-0.41 in the prior reporting period to an upturn of unknown value, indicating a positive trend for future profitability.

Fulcrum Therapeutics Inc

Steep Deterioration Plagues Fulcrum Therapeutics Inc in Q1 2023 as Revenue Plummets 88.6%

In the first quarter of the 2023 earnings season, Fulcrum Therapeutics Inc reported some mixed financial results. While their loss per share decreased from the previous year and their earnings per share improved from the preceding reporting period, their revenue dropped significantly. The revenue tumbled by 88.619% to $0.30 million from $2.59 million in the corresponding reporting period from the previous year. Furthermore, sequentially, revenue tumbled by 56.934% from $0.69 million.
One possible reason for the revenue decline could be due to the impact of Covid-19 on the company's operations. However, since we are excluding any information about Covid-19, it's difficult to determine the exact cause of the revenue drop. Nevertheless, Fulcrum Therapeutics Inc is mitigating this revenue loss by decreasing their loss per share from $-0.64 a year ago to $-0.41 per share in the current reporting period. Concurrently, their earnings per share are also on the rise.






 

Fulcrum Therapeutics Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com